Holen Sie sich die Stockscreener-App
2.86
3.44%
0.10
Handel nachbörslich:
2.86
Schlusskurs vom Vortag:
$2.76
Offen:
$2.8
24-Stunden-Volumen:
1.50M
Relative Volume:
3.32
Marktkapitalisierung:
$165.60M
Einnahmen:
$59.62M
Nettoeinkommen (Verlust:
$8.57M
KGV:
24.03
EPS:
0.119
Netto-Cashflow:
$-12.62M
1W Leistung:
+10.23%
1M Leistung:
+4.20%
6M Leistung:
+22.53%
1J Leistung:
+310.02%
1-Tages-Spanne:
$2.76
$2.945
1-Wochen-Bereich:
$2.55
$2.945
52-Wochen-Spanne:
$0.6562
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.86 | 159.81M | 59.62M | 8.57M | -12.62M | 0.119 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
SPRO Technical Analysis | Trend, Signals & Chart Patterns | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics (SPRO) Q1 2026 Earnings: Why the Beat MattersCEO Earnings Statement - Newser
Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price Today & Analysis - Gotrade
Is Spero Therapeutics (SPRO) 110.3% Overvalued After Q1 2026 Ear - GuruFocus
Spero Therapeutics 1Q Loss $7.2M >SPRO - Moomoo
Spero Therapeutics Q1 revenue drops on decreased clinical activity - TradingView
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update - The Manila Times
Spero Therapeutics (NASDAQ: SPRO) leans on GSK-partnered tebipenem ahead June 2026 FDA date - Stock Titan
Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spero Therapeutics (SPRO) trims Q1 2026 loss ahead key tebipenem FDA date - Stock Titan
FDA to rule June 18 on Spero oral antibiotic for severe UTIs - Stock Titan
TradingKey - TradingKey
MSN Money - MSN
Number of shareholders of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
SPRO SEC FilingsSpero Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics CEO sells $63,352 in company stock By Investing.com - Investing.com Australia
Spero Therapeutics (SPRO) officer sells shares for RSU tax obligations - Stock Titan
Spero Therapeutics CEO sells $63,352 in company stock - Investing.com India
SPRO: The fleeting Sparrow - Moomoo
No call planned as Spero sets May 13 for Q1 results update - Stock Titan
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - GlobeNewswire
SPRO Stock Price, Quote & Chart | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest - MarketBeat
Best Momentum Stock to Buy for October 10th - MSN
Spero Therapeutics (NASDAQ: SPRO) 2026 proxy adds stock increase and new incentive plan - Stock Titan
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
[ARS] Spero Therapeutics, Inc. SEC Filing - Stock Titan
ROSEN, Top Ranked Investor Counsel, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics (SPRO) Stock Volume Spike Alert (Builds on Momentum) 2026-04-20Open Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Spero Therapeutics (SPRO) Stock Insider Buying (Market Focus) 2026-04-18Algo Picks - Cổng thông tin điện tử tỉnh Lào Cai
SPRO Forecast, Price Target & Analyst Ratings | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics Stock Rises Above 50-Day Moving Average - National Today
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Spero Therapeutics (NASDAQ: SPRO) asks shareholders to double authorized shares to 240M - Stock Titan
Portfolio Shifts: Is Spero Therapeutics Inc stock showing strong momentum2026 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
MACD Signal: Does Spero Therapeutics Inc have pricing power2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
Can Spero Therapeutics (SPRO) Stock increase dividends | Price at $2.63, Down 5.40%Hot Community Stocks - Newser
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
Is Spero Therapeutics (SPRO) Stock undervalued by the market | Price at $2.73, Up 0.55%Top Trending Breakouts - Newser
Market Overview: Will Spero Therapeutics Inc benefit from seasonality2026 Pullbacks & Capital Efficiency Focused Ideas - baoquankhu1.vn
Market Review: What is the PEG ratio of Spero Therapeutics IncInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
Is Spero Therapeutics (SPRO) Stock Reacting to Market | Price at $2.73, Up 2.43%Institutional Flow - Newser
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spero Therapeutics Inc-Aktie (SPRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rajavelu Esther | See Remarks |
Feb 06 '26 |
Sale |
2.36 |
87,917 |
207,484 |
1,012,091 |
| Keutzer Timothy | Chief Operating Officer |
Feb 06 '26 |
Sale |
2.36 |
18,652 |
44,019 |
742,506 |
| Keutzer Timothy | Chief Operating Officer |
Feb 03 '26 |
Sale |
2.14 |
24,224 |
51,839 |
764,629 |
| Keutzer Timothy | Chief Operating Officer |
Feb 02 '26 |
Sale |
2.20 |
18,891 |
41,560 |
788,853 |
| Keutzer Timothy | Chief Operating Officer |
Feb 04 '26 |
Sale |
2.24 |
3,471 |
7,775 |
761,158 |
| Rajavelu Esther | See Remarks |
Feb 02 '26 |
Sale |
2.20 |
18,442 |
40,572 |
1,100,008 |
| Rajavelu Esther | See Remarks |
Nov 07 '25 |
Sale |
2.37 |
40,270 |
95,440 |
869,450 |
| Mahadevia Ankit | Director |
Aug 28 '25 |
Sale |
1.97 |
6,572 |
12,947 |
703,294 |
| Keutzer Timothy | Chief Operating Officer |
Aug 28 '25 |
Sale |
1.97 |
1,695 |
3,339 |
739,744 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):